▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent Articles by Taylor Carmichael

This_Under-the-Radar_Crypto_Bank_Is_Skyrocketing

Sep 15, 2021 by Taylor Carmichael

This Under-the-Radar Crypto Bank Is Skyrocketing

Silvergate Capital has emerged as a key company in the rise of cryptocurrencies.

Adyen_Is_a_Fintech_Monster_Stock

Sep 15, 2021 by Taylor Carmichael

Adyen Is a Fintech Monster Stock

This Dutch payments company is already a mega-cap and is still growing fast.

GettyImages-1201549319

Sep 15, 2021 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 COVID Stocks That Might Double Soon

Here are three healthcare stocks as nominees for a quick double in 2021.

getty-friends-talking-stocks

Sep 8, 2021 by Taylor Carmichael

2 Stocks I Bought Last Week

One is a small-cap that's using the franchise model with chiropractors, and one is a tiny biotech that just might be the biggest stock of 2022.

GettyImages-506712124

Sep 7, 2021 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

179538205_4086311104724320_3167924256785211127_n

Sep 4, 2021 by Taylor Carmichael

Why Figs Is the Starbucks of Scrubs

This fashion house for healthcare workers is creating an upscale brand out of a generic item.

GettyImages-155351397

Sep 2, 2021 by Taylor Carmichael

Here's How You Handle a Volatile Stock Like Cassava Sciences

Investing in biotech stocks can pay off big, but only if their research pans out. Pay attention to the risk-reward ratio -- and control your greed.

GettyImages-1186936189

Aug 31, 2021 by Taylor Carmichael, George Budwell, and Patrick Bafuma

COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?

Which subset of the COVID-19 healthcare market will outperform over the next year?

GettyImages-863481734

Sep 1, 2021 by Taylor Carmichael

Why the Cassava Sciences Bears Are Wrong

The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish?

GettyImages-108224060

Aug 27, 2021 by Taylor Carmichael

Which Biotech Stock Will Shock the Market in 2022?

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

GettyImages-1189508174

Aug 24, 2021 by Taylor Carmichael, George Budwell, and Zhiyuan Sun

Will Telehealth Stocks Thrive After COVID?

Internet healthcare companies have seen their revenue skyrocket during the pandemic. What will the future bring?

GettyImages-155351397

Aug 17, 2021 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Scary COVID Stocks to Avoid

Our Fool roundtable picks three COVID stocks they think are dangerous at these prices.

getty-person-riding-bike-top-mountain

Aug 15, 2021 by Taylor Carmichael

My 2019 Report Card: Up 319%

I made 63 bullish calls involving 45 companies in 2019. Here are the winners, the stinkers, and everything in between.

GettyImages-157399901

Aug 14, 2021 by Taylor Carmichael

Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?

Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results.

Why_Is_Biogen_Pursuing_a_New_Direction_in_Its_Alzheimer_s_Research

Aug 13, 2021 by Taylor Carmichael

Why Is Biogen Pursuing a New Direction in Alzheimer's Research?

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.

Is_There_Any_Hope_Left_for_This_Alzheimer_s_Drug_Developer

Aug 13, 2021 by Taylor Carmichael

Is There Any Hope Left for This Alzheimer's Drug Developer?

Biogen is reeling from charges that its drug doesn't work.

Will_Biogen_s_Aduhelm_Get_Yanked_From_the_Market

Aug 13, 2021 by Taylor Carmichael

Will Biogen's Aduhelm Get Yanked From the Market?

The FDA is requiring Biogen to run another study to prove efficacy. If Aduhelm fails to beat placebo in this study, the drug will be recalled from the market.

How_Much_Should_an_Alzheimer_s_Drug_Cost-_The_Answer_Is_More_Complicated_Than_You_d_Think

Aug 13, 2021 by Taylor Carmichael

How Much Should An Alzheimer's Drug Cost?

The answer is more complicated than you think.

Why_Is_Cassava_Sciences__Stock_So_Volatile

Aug 12, 2021 by Taylor Carmichael

Why Is Cassava Sciences' Stock So Volatile?

The stock is up 1,700% year to date.

Cassava_Sciences_vs._Biogen-_Who_Will_Emerge_Victorious_in_the_Race_to_Help_Alzheimer_s_Patients

Aug 12, 2021 by Taylor Carmichael

Cassava Sciences vs. Biogen

Who will emerge victorious in the race to help Alzheimer's patients?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services